200 patients with painful temporomandibular disorder1 were randomised to 9 weeks of either placebo or extended-release propranolol 60 mg BD starting at OD for the first week.2
In the end, there was no statistical difference between the groups, but when analysing a 50% reduction in scores, both outcomes were statistically significant, with a number needed to treat of 6.1. For the 50% reduction, it was 56% vs 39% respectively.
This is useful to know as there are several other treatments used for the condition with little or no evidence of benefit. The mechanism of action is thought to be the blocking of the adrenalin receptors, which may lead to less muscle spasm.
The extended-release tablet is not available in New Zealand, and an option would be to use 60 mg TDS or QID depending on tolerability.
References:
